Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenolol, Perindopril, and Verapamil in Marfan Syndrome
NCT01295047Phase 4
Key facts
- Status
- Completed
- Start
- Jul 2006
- Primary completion
- Dec 2007
- Countries
- 1
- Sponsor
- Cardiff University
- Modality
- Small Molecules
- Conditions
- Marfan syndrome (MFS)
01
Overview
Phase 4, randomised, double-blind trial of atenolol, perindopril and verapamil in Marfan syndrome (MFS), sponsored by Cardiff University. Primary endpoint: Central Arterial Pressure at 18 weeks. Started Jul 2006; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Patients aged 16-60 with Marfan syndrome, excluding those with prior aortic surgery/dissection, severe valvular disease, or large aortic diameter.
04
Endpoints
Primary
Central Arterial Pressure
Beyond the preview
Go deeper on NCT01295047.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295047.